There may be a future for cardiac myosin inhibitors in heart failure with preserved ejection fraction (HFpEF), according to the proof-of-concept EMBARK-HFpEF trial. An established cardiac myosin ...
Background There is a lack of contemporary data describing patients with left ventricular (LV) systolic dysfunction post ...
Verywell Health on MSN
Types of heart failure and how they affect you
Medically reviewed by Jeffrey S. Lander, MD Key Takeaways Heart failure happens when the heart can't pump enough blood ...
The Heart Failure Society of America (HFSA), the Heart Failure Association of the European Society of Cardiology (HFA of the ESC), and the Japanese Heart Failure Society (JHFS) announced today a new ...
Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...
Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.
Panelists discuss how ARNIs like sacubitril-valsartan provide superior outcomes compared with ACE inhibitors in HFrEF (20% reduction in cardiovascular events, 16% mortality reduction), with broad FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results